论文部分内容阅读
DNA甲基化是哺乳动物最常见的表观遗传学修饰方法之一,它能调控正常基因的表达、维持染色体的完整性,是调节DNA重组的关键环节,具有重要的生物学意义。DNA甲基化是肿瘤抑癌基因的沉默机制之一,普遍存在于所有基因类型,当正常甲基化过程发生异常变化时,会引起机体的一系列分子改变导致肿瘤的发生。DNA甲基化异常在肝癌的发生中发挥了重要作用,且与肝癌的进展与转移也存在相关性,但是其具体机制仍有待进一步研究阐明。本文就DNA甲基化与肝癌关系的研究进展及其可能的作用机制进行了总结,并对DNA甲基化抑制剂作为潜在抗癌药物的可能性进行了探讨,同时为肝癌的早期诊断与治疗提供新的研究思路。
DNA methylation is one of the most common epigenetic modification methods in mammals. It can regulate the expression of normal genes and maintain the integrity of chromosomes. It is a key link in DNA recombination and has important biological significance. DNA methylation is one of the silencing mechanisms of tumor suppressor genes. It exists universally in all genotypes. When abnormality occurs in normal methylation, it causes a series of molecular changes in the body leading to tumorigenesis. Aberrant DNA methylation plays an important role in the development of hepatocellular carcinoma (HCC), and is also correlated with the progression and metastasis of HCC. However, its specific mechanism remains to be elucidated. This article summarizes the research progress on the relationship between DNA methylation and hepatocellular carcinoma and its possible mechanism of action, and explores the possibility of DNA methylation inhibitor as a potential anti-cancer drug, as well as early diagnosis and treatment of liver cancer Provide new research ideas.